Overview

An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of paliperidone palmitate as compared with placebo in the treatment of participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions [a false belief held in the face of strong differing evidence, especially as a symptom of psychiatric disorder] and hallucinations [imagining things], and withdrawal into the self).
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.
Treatments:
Paliperidone Palmitate